Order Article Reprints

Leyh C, Heucke N, Schotten C, Büchter M, Bechmann LP, Wichert M, Dechêne A, Herrmann K, Heider D, Sydor S, et al. LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers. 2022; 14(19):4584. https://doi.org/10.3390/cancers14194584

Leyh, Catherine, Niklas Heucke, Clemens Schotten, Matthias Büchter, Lars P. Bechmann, Marc Wichert, Alexander Dechêne, Ken Herrmann, Dominik Heider, Svenja Sydor, and et al. 2022. "LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis" Cancers 14, no. 19: 4584. https://doi.org/10.3390/cancers14194584

Leyh, C., Heucke, N., Schotten, C., Büchter, M., Bechmann, L. P., Wichert, M., Dechêne, A., Herrmann, K., Heider, D., Sydor, S., Lemmer, P., Ludwig, J. M., Pospiech, J., Theysohn, J., Damm, R., March, C., Powerski, M., Pech, M., Özcürümez, M., ... Manka, P. P. (2022). LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers, 14(19), 4584. https://doi.org/10.3390/cancers14194584